EP Patent

EP4089076A1 — High-purity quinoline derivative and method for manufacturing same

Assigned to Eisai R&D Management Co Ltd · Expires 2022-11-16 · 4y expired

What this patent protects

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (A-1) is 60 ppm by mass or less.

USPTO Abstract

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (A-1) is 60 ppm by mass or less.

Drugs covered by this patent

Patent Metadata

Patent number
EP4089076A1
Jurisdiction
EP
Classification
—
Expires
2022-11-16
Drug substance claim
No
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.